Matching Items (122)
Filtering by

Clear all filters

137847-Thumbnail Image.png
Description
Glioblastoma multiforme (GBMs) is the most prevalent brain tumor type and causes approximately 40% of all non-metastic primary tumors in adult patients [1]. GBMs are malignant, grade-4 brain tumors, the most aggressive classication as established by the World Health Organization and are marked by their low survival rate; the median

Glioblastoma multiforme (GBMs) is the most prevalent brain tumor type and causes approximately 40% of all non-metastic primary tumors in adult patients [1]. GBMs are malignant, grade-4 brain tumors, the most aggressive classication as established by the World Health Organization and are marked by their low survival rate; the median survival time is only twelve months from initial diagnosis: Patients who live more than three years are considered long-term survivors [2]. GBMs are highly invasive and their diffusive growth pattern makes it impossible to remove the tumors by surgery alone [3]. The purpose of this paper is to use individual patient data to parameterize a model of GBMs that allows for data on tumor growth and development to be captured on a clinically relevant time scale. Such an endeavor is the rst step to a clinically applicable predictions of GBMs. Previous research has yielded models that adequately represent the development of GBMs, but they have not attempted to follow specic patient cases through the entire tumor process. Using the model utilized by Kostelich et al. [4], I will attempt to redress this deciency. In doing so, I will improve upon a family of models that can be used to approximate the time of development and/or structure evolution in GBMs. The eventual goal is to incorporate Magnetic Resonance Imaging (MRI) data into a parameterized model of GBMs in such a way that it can be used clinically to predict tumor growth and behavior. Furthermore, I hope to come to a denitive conclusion as to the accuracy of the Koteslich et al. model throughout the development of GBMs tumors.
ContributorsManning, Miles (Author) / Kostelich, Eric (Thesis director) / Kuang, Yang (Committee member) / Preul, Mark (Committee member) / Barrett, The Honors College (Contributor) / College of Liberal Arts and Sciences (Contributor)
Created2012-12
Description
Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition characterized by a wide range of symptoms and severities, affecting communication, behavior, and social interactions. With the prevalence of ASD rising to affect nearly 1 in 36 children in the United States, understanding and addressing the multifaceted needs of those with

Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition characterized by a wide range of symptoms and severities, affecting communication, behavior, and social interactions. With the prevalence of ASD rising to affect nearly 1 in 36 children in the United States, understanding and addressing the multifaceted needs of those with ASD is increasingly critical. This review explores the interplay between genetic, environmental, and immune factors in the onset of ASD, focusing on metabolic dysfunctions and the role of the gut-brain axis. Emerging research highlights the significance of abnormal metabolites and gut microbiota imbalances in contributing to the pathophysiology of ASD, suggesting that these factors may influence neurological function and behavior through modulating immune responses. Recent analyses have uncovered metabolic disturbances in ASD, affecting amino acid metabolism, glutathione metabolism, glycolysis and the TCA cycle, homocysteine metabolism, ketone body synthesis, and lipid metabolism. These disturbances offer insights into how metabolic dysfunctions may contribute to the neurological and behavioral features of ASD. Furthermore, the gut microbiota's role in immune responses and the controversial impact of antibiotic use on gut flora composition is important to the complexity of ASD and the need for a nuanced understanding of treatment effects. This review delves into the current understanding of metabolic dysfunctions in children with ASD, emphasizing the critical role of gut microbiota and the impact of antibiotic use. Specifically, this review discusses SCFAs, para-cresol, amino acid metabolites, and glutathione and their respective specific treatments. It also explores the potential of vitamin/mineral supplementation as a therapeutic strategy, highlighting significant improvements in metabolic markers and behavioral symptoms associated with ASD. The findings from key studies, including those by Adams et al., suggest that targeted nutritional interventions and careful management of gut health could offer promising avenues for improving the quality of life for individuals with ASD. The review also acknowledges the need for further research to confirm the long-term effects of these interventions and to develop personalized treatment approaches that consider the unique needs in individuals with ASD.
ContributorsNandakumar, Keshav (Author) / Adams, James (Thesis director) / Flynn, Christina (Committee member) / Barrett, The Honors College (Contributor) / Department of Psychology (Contributor)
Created2024-05